Supplement Award Program
HIV/AIDS Related Malignancies
Stimulates research on HIV-associated malignancies to foster multidisciplinary collaborations between Cancer and CFAR investigators by supporting one-year pilot research projects in HIV-associated malignancies. Pilot studies may include basic, translational, and clinical research on the etiology, pathogenesis, prevention, and management of AIDS-defining and non-AIDS-defining malignancies.
Supports a broad range of highly innovative research on: the alterations in HIV pathogenesis and the host immune response in the setting of TB co-infection; TB related immune reconstitution inflammatory syndrome (IRIS); the effect of TB on HIV clinical disease progression, and changes in latent TB activation and/or active disease progression in the setting of antiretroviral therapy.
Nanotechnology and HIV
Supports a broad range of highly innovative, nanotechnology-based research projects in the field of HIV and HIV-related co-infections such as tuberculosis and hepatitis. Technologies to prevent transmission or acquisition of HIV, improve treatment of HIV and its co-infections, and ultimately cure HIV infection are of particular interest.
HIV and Aging
The goal of this funding opportunity is to improve medical outcomes, functional status and quality of life in older patients with HIV/AIDS through improved understanding of interactions among aging processes, HIV viral infection, treatment effects and toxicities, and multiple morbidities commonly occurring in older persons.
HIV Vaccine Discovery
Supports a broad range of highly innovative research in HIV vaccine discovery, including novel assay/technology development, immunology, virology, cellular and structural biology and host genetics, and novel concepts and approaches applicable to the design of an effective prophylactic HIV vaccine.
Outside the Box AIDS Vaccine Award
Stimulates the discovery, design and preclinical evaluation of highly innovative approaches that could provide long term protection from acquiring HIV infection. Applicants are expected to explore novel hypotheses or address difficult problems, the solutions to which could have a significant impact on finding methods to interrupt HIV transmission.
Learn more about current CFAR Supplement Opportunities.
Active Supplement Awards
Physical Frailty and Sarcopenia in HIV/AIDS Older Adults
Design of optimal multi-epitope vaccines to elicit CD4 T cell immunity to HIV (HIV Vaccine Discovery)
Using Nanotechnology to Improve Mucosal Delivery of Candidate HIV-1 Vaccines (Nanotechnology and HIV)
Oral Cavity Squamous Cell Carcinoma and Oral Microbiota in HIV-Positive Individuals (HIV/AIDS Related Malignancies)
CD40L connects Aging, HIV-1 and Malignancy (HIV/AIDS Related Malignancies)
UR Named Center for AIDS Research by the National Institutes of Health »
May 09, 2013
As Our Understanding of HIV Evolves, Grant Helps Providers Keep Pace »
February 19, 2013
URMC Observes World AIDS Day with Talks, Events, Concert »
November 19, 2012
URMC Observes HIV Vaccine Awareness Day with Events »
May 11, 2012
New Fund Will Support Early Stage Drug Discovery »
April 09, 2012
Justice Involved Women Conference
Join us for the June 21st Justice Involved Women Conference where researchers, practitioners and policy makers will present their work to disseminate evidence-based practices and interventions for justice involved women. Other discussion topics will include the state of the science, difficulties for informing practice, funding challenges and solutions for justice involved women. Click here to learn more.